SHSE:600976 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SHSE:600976 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Jianmin Pharmaceutical Group Co's sale of investment for the three months ended in Sep. 2024 was ¥102 Mil. It means Jianmin Pharmaceutical Group Co gained ¥102 Mil from selling investments. Jianmin Pharmaceutical Group Co's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was ¥125 Mil.
Compared with last quarter (¥17 Mil in Jun. 2024 ), Jianmin Pharmaceutical Group Co gained more money from selling investments in Sep. 2024 (¥102 Mil).
The historical data trend for Jianmin Pharmaceutical Group Co's Sale Of Investment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jianmin Pharmaceutical Group Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Sale Of Investment | Get a 7-Day Free Trial | 26.77 | 79.71 | 36.30 | 183.80 | 107.54 |
Jianmin Pharmaceutical Group Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Sale Of Investment | Get a 7-Day Free Trial | 4.35 | 3.76 | 2.33 | 16.79 | 101.86 |
Sale of Investments represents cash inflow on the sale of investments in securities.
Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥125 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Jianmin Pharmaceutical Group Co's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.
Du Ming De | Director | |
He Qin | Director | |
Gao Kai | senior management | |
Wang Jun | senior management | |
Huang Zhi Jun | senior management | |
Pei Xue Jun | senior management | |
Bu Zhong Jiang | Director | |
Cheng Chao Yang | senior management | |
Xu Sheng | senior management | |
Hu Zhen Bo | senior management | |
Liu Qin Qiang | Director | |
Xiong Fu Liang | senior management | |
Liu Peng | senior management |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.